Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimal MTX Dose With Folic Acid Randomized Case-control Trial (MTXFARCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04066803
Recruitment Status : Recruiting
First Posted : August 26, 2019
Last Update Posted : August 26, 2019
Sponsor:
Collaborator:
Shanghai Pharmaceuticals Holding Co., Ltd
Information provided by (Responsible Party):
Gu Jieruo, Sun Yat-sen University

Brief Summary:

This is an open, single-center, randomized,case controlled, prospective study. Previous studies in China lacked data of efficacy and safety of optimal methotrexate (MTX) dose with/without other anti-rheumatoid drugs (DMARDs) in the treatment of rheumatoid arthritis (RA) .Meanwhile there was no study on the optimal folic acid dose in aspect of preventing side effects of MTX. So we designed the experiment below.

The research planned to recruit 160 RA patients in Meizhou, Guangdong Province,China. The volunteers had no relief with 10 mg of MTX per week with/without other DMARDs for at least 3 month. They were randomly divided into 1:1 groups. The experimental group would be treated with original dMARDs ,incremental MTX( gradually increased to the optimal dose (0.3 mg/kg) in the first 12 weeks)and folic acid (the dose adjusted as appropriate with range from 5 mg to 90 mg per week) . While the control group would be treated with original MTX(10mg per week) and incremental original dMARDs( gradually increased to the maximum dose in the first 12 weeks). The two groups would keep the 12th week treatment last to the 36th week, and the efficacy and safety indexes would be evaluated during the whole study.

The objective of the study was to determine the efficacy and safety of the optimal dose of MTX in Chinese patients with rheumatoid arthritis, and to determine the efficacy and optimal prevention dose of folic acid in Chinese RA patients. It might be helpful for Chinese rheumatologists to use MTX accurately and efficiently to treat RA patients in clinical work.


Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: MTX Drug: Folic Acid Drug: DMARDs Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Optimal Methotrexate With Folic Acid in Patients With Rheumatoid Arthritis in Meizhou, Guangdong: a Randomized Case-control Study
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : July 30, 2020
Estimated Study Completion Date : July 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MTX group with folic acid
the group with optimal MTX dose (gradually increased from 0 to 12weeks,appropriate folic acid,and stable original other DMARDs
Drug: MTX
MTX group would be intervened by incremental MTX and folic acid,while the control group would be intervened by incremental original DMARDs they already used(including Leflunomide,Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)

Drug: Folic Acid
MTX group would be intervened by folic acid,while the control group would be not intervened by folic acid

Drug: DMARDs
including Leflunomide,Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony

Active Comparator: control group without folic acid
the group with stable MTX 10mg/w dose and maximum DMARDs doses(graduallly increased from 0 to 12 weeks)without folic acid
Drug: MTX
MTX group would be intervened by incremental MTX and folic acid,while the control group would be intervened by incremental original DMARDs they already used(including Leflunomide,Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)

Drug: DMARDs
including Leflunomide,Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony




Primary Outcome Measures :
  1. The response rate of ACR20 at the 36th weeks [ Time Frame: at the 36th weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. According to the revised 1987 American Academy of Rheumatology (ACR) RA classification criteria, subjects must be diagnosed as rheumatoid arthritis ≥6 months.
  2. MTX was given 10 mg/week(not the maximum dose of MTX (calculated as 0.3 mg/kg)) for ≥3 months before admission.
  3. At the screening and baseline phases, the number of swollen joints (SJC) should be ≥1 (counting 66 joints), and the number of tender joints (TJC) should be ≥ 1 (counting 66 joints); the ESR should be ≥20 mm/h, and/or the CRP should be ≥ 10 mg/l;
  4. The age of the subjects ranged from 18 to 70 years.
  5. The following RA drugs can be used in combination within 3 months before admission; oral glucocorticoid (prednisone ≤10 mg/d or its equivalent), non-steroidal anti-inflammatory drugs (≤ the maximum recommended dose), leflunomide, hydroxychloroquine, sulfasalazine, total paeoniflorin, Tripterygium glycoside, azathioprine, and MTX. The stable dose of DMARDs should be at least 4 weeks before baseline, and the combined dose of DMARDs beside MTX could not reach the full dose.
  6. Women of childbearing age should agree to take effective contraceptive measures during the trial period;
  7. The urinary pregnancy test of women of childbearing age was negative at screening time.
  8. Understand the steps and contents of the experiment and sign the informed consent to participate in the experiment.

Exclusion Criteria:

  1. Those who underwent major surgery (including joint surgery) within 8 weeks before screening or who planned major surgery within 6 months after random selection;
  2. Patients with autoimmune diseases except RA include SLE, MCTD, scleroderma and polymyositis. But subjects with RA and secondary Sjogren syndrome were allowed to participate in the trial.
  3. Inflammatory arthritis (such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) .
  4. Intra-articular injection or other injection of corticosteroids within 4 weeks before baseline;
  5. Those who had been vaccinated with live/inactivated vaccine within 4 weeks before baseline;
  6. Three months before admission, the following drugs were used: cyclophosphamide, biological agents and folic acid.
  7. DMARDs dose reached maximum dosage in 3 months before admission, or DMARDs≥3 were used in 3 months before admission
  8. Subjects with severe uncontrolled diseases including cardiovascular disease, nervous system disease, pulmonary disease (including obstructive pulmonary disease and interstitial lung disease), nephropathy, liver disease, endocrine disease (including uncontrolled diabetes mellitus) and gastrointestinal diseases;
  9. known history of active or recurrent bacterial, viral, fungal, Mycobacterium or other infections (including, but not limited to, tuberculosis and atypical mycobacterium diseases, chest X-rays showing granulomatous diseases, hepatitis B and C, HIV infection, herpes zoster, but excluding Onychomycosis) ,any infection requiring hospitalization and intravenous antibiotic therapy within 4 weeks before screening ,or oral antibiotic therapy within 2 weeks before screening; active hepatitis B refers to HBsAg-positive patients without antiviral drugs and HBV-DNA > 10^4; active hepatitis C refers to anti-HCV-positive patients without antiviral drugs and HCV-RNA > 10^4;
  10. Subjects with a history of malignant tumors, including solid tumors and hematological malignancies (except excised or cured skin basal cell carcinomas);
  11. Pregnant or lactating women (breastfeeding);
  12. Subjects with neuropathy and other painful diseases may interfere with pain assessment.
  13. Serum creatinine > 1.5 mg/dl (equivalent to 133 umol/L);
  14. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times of the upper limit of normal value (if ALT or AST is greater than 2 times of the upper limit of normal value for the first time, it should be sampled again during the screening period), or total bilirubin is greater than the upper limit of normal value (if total bilirubin is greater than the upper limit of normal value for the first time at the screening, sampling should be done again during the selection period).
  15. Platelet count < 100 x 10^9/L, or white blood cells < 3 x 10^9/L;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04066803


Contacts
Layout table for location contacts
Contact: Dong Fang Lin, Doctor 8618688493601 619849304@qq.com
Contact: Yan Li Zhang, Doctor 8613430278467 zhangyanli04386@163.com

Locations
Layout table for location information
China, Guangdong
the 3rd Affiliated Hospital of Sun Yat-sen University Recruiting
Guangzhou, Guangdong, China, 510630
Contact: Dong Fang Lin, Doctor    8618688493601    619849304@qq.com   
Contact: Yan Li Zhang, Doctor    8613430278467    zhangyanli04386@163.com   
Principal Investigator: Dong Fang Lin, Doctor         
Sub-Investigator: Qi Yun Chen, Master         
Sub-Investigator: Yi Quan Wen, Master         
Sub-Investigator: Yan Li Zhang, Doctor         
Sub-Investigator: Xu Li Song, Bachelor         
Sub-Investigator: Qing Lv, Doctor         
Sub-Investigator: Xiqing Luo, Bachelor         
Sub-Investigator: Yun Feng Pan, Master         
Sponsors and Collaborators
Sun Yat-sen University
Shanghai Pharmaceuticals Holding Co., Ltd
Investigators
Layout table for investigator information
Study Director: Yun Feng Pan, Master the 3rd Hospital of Sun Yat-sen University
Publications of Results:
Layout table for additonal information
Responsible Party: Gu Jieruo, Rheumatology Department, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT04066803    
Other Study ID Numbers: QHJH201805
First Posted: August 26, 2019    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No plan to share.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Folic Acid
Hematinics
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs